CORZ Core Scientific, Inc./tx Insider Trading

Director Weiss buys 7,000 CORZ shares at $14.53; stock now $15.46 but down 32.5% from 52-week high amid -37.5% revenue decline.

Weiss Eric Stanton, a director at Core Scientific, purchased 7,000 shares at $14.53 on 2026-03-09, increasing his holdings to 252,262 shares. This buy occurs against a backdrop of significant company stress: revenue declined 37.5% year-over-year, the company reported a net loss of $146,660,000 in its latest quarter, and the stock has fallen 32.5% from its 52-week high of $22.90. At his same ticker (CORZ), Weiss's prior 4 buys showed mixed near-term outcomes (30-day range: -20.6% to +30.4%) but a strong 90-day timing pattern, with 3 of 4 prior purchases ultimately followed by gains. His cross-ticker track record shows a 75.00% 90-day win rate with an average 90-day return of +85.4%, though recent 30-day performance has been weak (average -1.4%). The purchase represents a 2.9% net increase to his CORZ position in a stock trading near the bottom of its annual range, but the company's deteriorating fundamentals—unprofitability and steep revenue contraction—create substantial execution risk regardless of historical insider timing accuracy.

CORZ Director Weiss buys 5,000 shares at $21.50; stock down 10.1% from 52-week high, but +20.4% in 30 days. Prior buys at CORZ all well-timed at 90-day mark.

Director Eric Stanton Weiss purchased 5,000 shares at $21.50, near the 52-week high of $22.90, during a strong 30-day run (+20.4%) and exceptional 90-day rally (+42.9%). Weiss's track record at CORZ is notable: his 3 prior purchases were all well-timed at the 90-day mark (posting +48.5%, +84.5%, and +225.5% respective 90-day returns), suggesting disciplined entry points or favorable timing luck. His cross-ticker record shows 100% win rate on buys with a 90-day average return of +119.5%. However, Core Scientific remains unprofitable (full-year net income: $-146.7M, latest quarter net income: $-146.7M) with minimal revenue growth (+1.6% annual), raising questions about valuation sustainability. The current price of $20.59 is already -10.1% below the transaction, indicating the near-term rally may be reversing.

Director Rozov Yadin purchased 110.0K shares of CORZ at $10.87 on 2025-05-28 (total value $1.2M), expanding stake 30.1% to 475.7K shares.

Director Rozov Yadin executed a substantial open-market purchase of 110,000 shares valued at $1,195,370.00, increasing his holdings by 30.1% to 475,687 shares. His prior transaction history at this ticker shows strong 90-day outcomes: his March 2024 buy returned +220.4% over 90 days, and his November 2024 sell was well-timed (down 34.6% 90-day post-sale), indicating consistent pattern recognition over a two-trade span. However, the current price of $10.69 sits -41.4% from the 52-week high and -1.7% below the purchase price, placing this buy 30 days into a +29.0% monthly rebound from lower levels. The company's full-year net income was negative, yet the latest quarterly net income shows $580.7M—a critical discrepancy that warrants clarity on one-time items, restructuring charges, or accounting methodology before assessing whether this purchase reflects genuine operational improvement or a temporary swing in reported earnings.

Director Weiss buys 6,000 CORZ shares at $8.46; stock down -57.3% from 52-week high, yet insider's 2 prior CORZ buys yielded +30.4% and +225.5% at 90 days.

Director Eric Stanton Weiss purchased 6,000 shares at $8.46 on 2025-03-06, a discretionary open-market buy that increased his holdings from 215.7K to 221.7K shares. The stock is currently trading at $7.78, down -57.3% from its 52-week high of $18.23 and -38.8% over the preceding 30 days, suggesting a period of significant momentum loss. However, Weiss's prior transaction history at this ticker provides important context: his previous buys on 2024-09-09 and 2024-03-15 delivered 90-day returns of +30.4% and +225.5% respectively, and both trades proved well-timed by the 90-day mark. The current acquisition occurs against a fundamentals backdrop of company-wide unprofitability ($-455.3M net income in the latest full fiscal year) and minimal revenue growth at +1.6% annually, yet the insider's demonstrated pattern of well-timed entry points at this security warrants investor attention as a potential contra-sentiment signal during a period of sharp drawdown.

Director Levy Jordan bought 62,500 CORZ shares at $8.01 (now $7.85); stock down 56.9% from 52-week high, down 35.7% in 30 days.

Director Levy Jordan purchased 62,500 shares at $8.01, increasing his holdings by 25.6% to 306,887 shares in a sharply declining stock. His prior buy at CORZ on 2024-08-20 delivered +13.9% 30-day and +53.0% 90-day returns, marking one of his cross-ticker track record of well-timed buys (1 prior buy, 100% win rate on 90-day returns). However, the current purchase arrives after Core Scientific has fallen 56.9% from its 52-week high and 35.7% in just 30 days, creating a pronounced mismatch between the insider's historical timing pattern and present market conditions. The company remains unprofitable (annual net income $-455.3M) despite modest revenue growth of 1.6%, and the stock has continued to deteriorate sharply in the weeks surrounding this filing. The concentration of a director's incremental 25.6% position increase during a period of acute downward momentum warrants close monitoring of company fundamentals and forward guidance.

Director Becker Todd A sold 134,250 shares of CORZ at $10.75 on 2025-03-03, reducing stake by 40.7%; stock now $9.60, down 47.3% from 52-week high.

Director Becker Todd A executed a substantial sale of 134,250 shares at $10.75, liquidating 40.7% of his holdings in Core Scientific. The stock has deteriorated significantly since the transaction, trading 47.3% below its 52-week high of $18.23 and 10.7% below his transaction price, suggesting the sale occurred before a continued decline. The company's fundamentals remain challenged: it reported a net loss of $455,259,000.00 against quarterly revenue of $95,354,000.00, underlining persistent unprofitability. The director's prior purchase at CORZ on 2024-03-15 proved exceptionally well-timed with a 90-day return of +212.2%, but this subsequent substantial reduction in exposure differs sharply from that earlier accumulation pattern.

Core Scientific CEO Sullivan sold 369,712 shares at $16.24 on 2025-01-24; stock now -38.0% from 52-week high at $11.31

Sullivan Adam Taylor, Chief Executive Officer, sold 369,712 shares of CORZ at $16.24 on 2025-01-24 for a total value of $6,003,753.17, reducing his holdings from 4,128,505 to 3,758,793 shares (-9.0% of pre-transaction holdings). The sale occurred when the stock was trading well above its current price of $11.31, which now sits -38.0% from the 52-week high and -19.5% over the past 30 days. Core Scientific is unprofitable with net income of $-455,259,000.00 on quarterly revenue of $95,354,000.00, and the company faced a -21.5% annual revenue decline. This represents the CEO's second open-market sale at this ticker within 22 days; his prior buy at CORZ on 2024-03-15 delivered a +221.7% 90-day return, but the current pricing environment has deteriorated significantly since the January 24 sale execution.

CORZ CEO Adam Taylor Sullivan sold 88,380 shares at $14.24 on 2025-01-02; stock now at $15.38, down 15.6% from 52-week high.

Sullivan Adam Taylor, Chief Executive Officer of Core Scientific, sold 88,380 shares for a total value of $1,258,796.34 at $14.24 per share, reducing his holdings by 2.1%. The transaction occurred as the stock trades 15.6% below its 52-week high of $18.23 and has declined 12.0% over the prior 30 days. Core Scientific reported a net loss of $455,259,000.00 in its most recent period against revenue of $95,354,000.00, and the company experienced annual revenue decline of 21.5%, signaling material operational stress. While Sullivan's cross-ticker track record shows strong long-term timing (100% 90-day win rate), his prior trade at CORZ in March 2024 returned +221.7% over 90 days, creating a baseline of successful positioning at this specific security. The current sale against a backdrop of negative earnings, shrinking revenue, and a stock retreating from recent highs warrants monitoring of company fundamentals and further insider activity.

Todd Duchene sells 132,810 shares (132.8K) at avg $14.25; retains 2,048,700 shares in Bitcoin miner as stock falls 12.0% in 30 days vs 52-week high $18.23.

Todd Duchene executed 2 separate sales totaling 132,810 shares for $1,892,571.84 on January 2-3, 2025, reducing his stake by 6.1% while retaining substantial holdings of 2,048,700 shares. The sales occurred at an average price of $14.25, occurring as Core Scientific's stock has declined 12.0% over the prior 30 days and trades 15.6% below its 52-week high of $18.23. The company faces significant operational headwinds: full-year net income was negative at $-455,259,000.00, annual revenue contracted 21.5% year-over-year, and the latest quarterly revenue of $95,354,000.00 reflects continued shrinkage. The timing of the sale follows a 26.2% 90-day gain, after which the stock has retreated sharply. Given Duchene's continued substantial ownership post-transaction, this activity does not signal full conviction loss, but the sale size and market conditions warrant investor scrutiny of the company's near-term trajectory.

Director Rozov Yadin sold 105.0K shares of CORZ at $18.11; remaining 345.2K shares. Stock now at $18.23 after +34.8% 30-day rally.

Rozov sold 105,000 shares (23.3% of prior holdings) at $18.11 during a period of strong momentum: the stock has risen +34.8% over 30 days and +69.4% over 90 days, currently trading at its 52-week high of $18.23. The timing is noteworthy given his cross-ticker track record shows 100% success rate on 3 prior buys with average 90-day returns of +159.5%, yet at Core Scientific specifically, his prior March 2024 buy resulted in a +220.4% gain over 90 days—a substantially more volatile outcome than his cross-ticker average. The company remains unprofitable (net income $-455.3M in the latest full year) with shrinking revenue (-21.5% annual growth), creating a disconnect between the stock's valuation momentum and fundamental deterioration. The sale occurred just 20 months after his prior purchase at this ticker, suggesting a reassessment of holdings after significant gains.